Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Endocrinology
Thyroid Cancer
Questions discussed in this category
What factors aside from progression do you consider most important in determining whether a patient with metastatic papillary thyroid carcinoma is radioactive iodine refractory?
What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?
1 Answer available
How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?
2 Answers available
Is dosimetry more important than preparation (ie rhTSH versus THW) when treating thyroid cancer with radioactive iodine therapy?
1 Answer available
What is the role of radiation therapy for an elderly patient with medullary thyroid cancer who is not a surgical candidate?
What techniques and doses would you prescribe to the primary and regional nodes?
1 Answer available
When would you offer post-operative concurrent chemoradiation in anaplastic thyroid cancer?
Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?
1 Answer available
What is the next step in management of a thyroid nodule that was biopsied and classified as Bethesda III, but Afirma genetic testing reveals parathyroid signature?
Patient does not have hypercalcemia.
2 Answers available
When would you offer radiation for poorly differentiated thyroid cancer?
3 Answers available
How would you approach patient with metastatic anaplastic thyroid cancer with NGS revealing only ARID1A mutation?
1 Answer available
20284
20370
19945
19223
8030
18835
15521
8963
Papers discussed in this category
Cancer discovery, 2015-07
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
J Immunother Cancer,
alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy.
Related Topics in Endocrinology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Genitourinary Cancers
Melanoma/Skin Cancer